“Will Washington Find the Cure for Cancer?”
In the July 12, 2011 edition of The Wall Street Journal, Kenneth C. Frazier cited in an op-ed piece the Booz & Company research that six of the top 10 U.S. companies in global research and development expenditures are biopharmaceutical companies. Mr. Frazier, the President and CEO of Merck & Co., referred to Booz & Company in support of his premise that the actions and proposals of the U.S. Government “significantly impede innovation in my industry—biopharmaceuticals—for the foreseeable future.” The Booz & Company Perspective, The Missing Link in Pharmaceutical R&D: Scientific Leaders Are Essential to Success, by Charley Beever, Anna Pettersson, Greg Rotz and August Vlak (all North America) points to an unexpected and unheralded source of potential productivity in the quest to discover new drugs—mid-level managers in the R&D function. Pharmaceutical companies can raise their productivity significantly, the co-authors write, by recognizing and activating the unique impact of leaders across the middle.